Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.

Revenue
+15.1%
EPS
+62.5%
Free cash flow
−9.63%

Quarter to September 2026, against a year earlier

24.14 0.14 +0.58%
Market cap
$1.9B
P/E
15.2×
Fwd P/E
45.2×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
ROE

+8 more TTM periods

5.34% 6.93% 8.77% 9.43%
Piotroski F-Score
8 8 8 7
ROA
4.90% 6.40% 8.09% 8.63%
ROIC
4.03% 5.35% 7.32% 4.33%
Return on Tangible Assets
14.72% 18.01% 21.44% 31.05%
Average Days of Receivables
31.52 33.76 35.19 35.63
Free Cash Flow per Share
1.61 1.95 2.08 2.01
Free Cash Flow
126.63 155.34 165.99 161.95
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026